【佳學(xué)基因靶向藥物基因檢測】前列腺癌的 DNA 損傷修復(fù)缺陷和靶向放射性核素治療：突變真的很重要嗎？系統(tǒng)回顧

如何知道我是否有經(jīng)典基因評價

探索腫瘤的基因組學(xué)特征與治療方案設(shè)計到了《Life (Basel)》在?2022 Dec 24;13(1):55.發(fā)表了一篇題目為《Review》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Luca Filippi,?Barbara Palumbo,?Oreste Bagni,?Viviana Frantellizzi,?Giuseppe De Vincentis,?Orazio Schillaci等完成。促進(jìn)了腫瘤的正確治療與個性化用藥的發(fā)展，進(jìn)一步強調(diào)了基因信息檢測與分析的重要性。

腫瘤基因檢測及靶向藥物治療研究關(guān)鍵詞：

聚苯乙烯,正確腫瘤學(xué),前列腺癌;放射性核素治療,鐳。

腫瘤治療檢測基因臨床應(yīng)用結(jié)果

本綜述的目的是評估 DNA 損傷修復(fù) (DDR) 突變對接受 [223Ra]RaCl2 放射性核素治療（223Ra 療法）的晚期前列腺癌 (PCa) 患者 (pts) 的反應(yīng)和結(jié)果的影響或前列腺特異性膜抗原 (PSMA) 配體。使用兩個主要數(shù)據(jù)庫根據(jù) PRISMA 標(biāo)準(zhǔn)進(jìn)行系統(tǒng)的文獻(xiàn)檢索。僅選擇了截至 2022 年 10 月以英語發(fā)表且納入患者≥10 名的研究。選擇了七項研究，包括 326 名患者，其中 201 名 (61.6%) 患有 DDR 缺陷。大多數(shù)選定的論文都是回顧性的，七分之四 (57.1%) 的樣本量較小 (<50 pts)。七項研究中的三項 (42.8%) 報告了與沒有 DDR 缺陷的受試者相比，在使用 α 發(fā)射體（223Ra 療法或 [225Ac]Ac-PSMA-617）治療后，有更有利的結(jié)果（總體或無進(jìn)展生存期）突變。在兩項使用 alpha 或 beta 發(fā)射器 ([177Lu]/[225Ac]-PMSA) 的研究中，沒有顯著的益處被記錄在懷有 DDR 缺陷的患者中。在除一篇論文外的所有論文中，有或沒有 DDR 突變的患者的反應(yīng)率沒有顯著差異。盡管初步數(shù)據(jù)和回顧性設(shè)計存在偏差，但初步數(shù)據(jù)表明，接受 α 發(fā)射體放射性核素靶向治療的攜帶 DDR 缺陷的 PCa 患者有更長的生存期。正確腫瘤學(xué)；前列腺癌;放射性核素治療；鐳。

腫瘤發(fā)生與革命國際數(shù)據(jù)庫描述：

The aim of the present review was to assess the impact of DNA damage repair (DDR) mutations on response and outcome of patients (pts) affected by advanced prostate cancer (PCa) submitted to radionuclide therapies with [223Ra]RaCl2?(223Ra-therapy) or prostate specific membrane antigen (PSMA) ligands. A systematic literature search according to PRISMA criteria was made by using two main databases. Only studies published up until to October 2022 in the English language with ≥10 enrolled patients were selected. Seven studies including 326 pts, of whom 201 (61.6%) harboring DDR defects, were selected. The majority of selected papers were retrospective and four out of seven (57.1%) had small sample size (<50 pts). Three out of seven (42.8%) studies reported a more favorable outcome (overall or progression free survival) after therapy with alpha emitters (223Ra-therapy or [225Ac]Ac-PSMA-617) in subjects with DDR defects with respect to those without mutations. In two studies employing alpha or beta emitters ([177Lu]/[225Ac]-PMSA), no significant benefit was registered in pts harboring DDR defects. In all but one paper, no significant difference in response rate was reported among pts with or without DDR mutations. Although preliminary and biased by the retrospective design, preliminary data suggest a trend towards a longer survival in PCa pts harboring DDR defects submitted to radionuclide targeted therapy with alpha emitters.Keywords:?PSMA; precision oncology; prostate cancer; radionuclide therapy; radium.